SPRY stock drops after ARS says no new neffy coverage decisions in July formulary cycle.

SPRY stock drops after ARS says no new neffy coverage decisions in July formulary cycle.

ARS Pharmaceuticals stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray to its formulary.